Evaluation of blood glucose changes with regular versus rapid-acting insulin for hyperglycaemia management in the emergency department

被引:1
|
作者
Zou, Xiaoxu [1 ,2 ]
Treu, Cierra N. [1 ,3 ,5 ]
Laub, Jessica [1 ]
Mendoza, Christopher [4 ]
机构
[1] NewYork Presbyterian Brooklyn Methodist Hosp, Dept Pharm, Brooklyn, NY USA
[2] Coram Healthcare, Dept Pharm, Syracuse, NY USA
[3] NYC Hlth Hosp South Brooklyn Hlth, Dept Data Management, Brooklyn, NY 11235 USA
[4] NewYork Presbyterian Brooklyn Methodist Hosp, Dept Emergency Med, Brooklyn, NY USA
[5] NYC Hlth Hosp South Brooklyn Hlth, Clin Informat, 2601 Ocean Pkwy,Room 10E18, Brooklyn, NY 11235 USA
关键词
diabetes; medication review; patient safety; pharmaceutical care; repeat medication; SYNERGY;
D O I
10.1093/ijpp/riad058
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives As emergency department (ED) visits secondary to hyperglycaemia increase, goals should focus on optimising treatment to minimise the length of stay (LOS). Both regular and rapid-acting insulins can effectively treat hyperglycaemia, but have different pharmacokinetic profiles. The purpose of this study is to compare blood glucose (BG) reduction over time in patients receiving subcutaneous regular versus rapid-acting insulin in the ED. Methods This retrospective chart review from 1 January 2018 to 31 December 2020 included adult ED patients with a BG & GE;200 mg/dl who received subcutaneous regular insulin or insulin aspart. The primary endpoint was a change in BG immediately before and & GE;30 min after insulin administration over time. Results There were 279 patients included in the study (108 regular insulin and 171 insulin aspart). Change in BG over time was 41.5 mg/dl/h in the regular insulin group and 47 mg/dl/h in the insulin aspart group (P = 0.36). There was no difference in hypoglycaemic events, ED LOS, time from insulin administration to discharge and total change in BG during ED stay. Patients who received regular insulin required less additional insulin doses (8.3% vs. 18.1%, P = 0.02), received a greater volume of intravenous fluids (1629 ml vs. 1280 ml, P = 0.02) and higher weight-based dose for the first insulin dose (0.11 units/kg vs. 0.10 units/kg, P = 0.02). Conclusion There was no significant difference in BG reduction between insulin types for hyperglycaemic patients treated in the ED. This suggests that regular insulin and rapid-acting insulin have similar efficacy in the treatment of hyperglycaemia in the ED.
引用
收藏
页码:534 / 539
页数:6
相关论文
共 50 条
  • [1] Safety of Rapid-Acting Insulin Analogs Versus Regular Human Insulin
    Kitabchi, Abbas E.
    Gosmanov, Aidar R.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 344 (02): : 136 - 141
  • [2] Pharmacodynamic properties of Viaject™:: A novel rapid-acting regular human insulin
    Steiner, Solomon S.
    Hompesch, Marcus
    Pohl, Roderike
    Simms, Patrick
    Pfuetzner, Andreas
    Forst, Thomas
    Heinemann, Lutz
    DIABETES, 2006, 55 : A27 - A27
  • [3] Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
    Nicolucci, Antonio
    Ceriello, Antonio
    Di Bartolo, Paolo
    Corcos, Antonella
    Orsini Federici, Marco
    DIABETES THERAPY, 2020, 11 (03) : 573 - 584
  • [4] Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
    Antonio Nicolucci
    Antonio Ceriello
    Paolo Di Bartolo
    Antonella Corcos
    Marco Orsini Federici
    Diabetes Therapy, 2020, 11 : 573 - 584
  • [5] Use of rapid-acting insulin analog as the baseline infusion during glucose clamping improves pharmacokinetic evaluation
    Cassidy, James
    Baughman, Robert
    Tonelli, George
    Boss, Anders
    Hernandez, Bobbie
    Schwartz, Sherwyn
    DIABETES, 2007, 56 : A159 - A160
  • [6] The use of rapid-acting insulin analogue as the baseline infusion during glucose clamping improves pharmacokinetic evaluation
    Cassidy, J.
    Baughman, R.
    Tonelli, G.
    Boss, A.
    Hernandez, B.
    Schwartz, S.
    DIABETOLOGIA, 2007, 50 : S396 - S396
  • [7] Regular insulin is as effective as rapid-acting insulin analogs in combination with glargine insulin in type 1 diabetic patients
    Ampudia-Blasco, FJ
    Girbés, J
    Sanz, J
    Pedro, T
    Martínez, S
    Catalá, M
    Carmena, R
    DIABETOLOGIA, 2005, 48 : A92 - A92
  • [8] THREE-YEAR HEALTH CARE EXPENDITURES IN DIABETIC PATIENTS RECEIVING RAPID-ACTING INSULIN ANALOGUES VERSUS THOSE ON HUMAN REGULAR INSULIN
    Cammarota, S.
    Bruzzese, D.
    Catapano, A. L.
    Citarella, A.
    De, Luca L.
    Manzoli, L.
    Masulli, M.
    Menditto, E.
    Mezzetti, A.
    Riegler, S.
    Riccardi, G.
    VALUE IN HEALTH, 2013, 16 (07) : A451 - A451
  • [9] Examining the glycaemic and hypoglycaemic benefits with rapid-acting insulin analogues: a meta-analysis of insulin aspart versus regular human insulin in randomised controlled trials
    Heller, S.
    Bode, B. W.
    Kozlovski, P.
    Svendsen, A.
    DIABETOLOGIA, 2009, 52 : S359 - S360
  • [10] Rapid-Acting Insulin Analog Can Decrease a Hypoglycemic Risk, and Control Blood Glucose Drifting in the Surgical Diabetic Patients
    Ueno, Hiroki
    Yakushiji, Yosuke
    Isaka, Yoshihiro
    Hosokawa, Yuki
    Murayama, Masahiro
    Tanaka, Nagaaki
    Yamagami, Keiko
    Kawasaki, Isao
    Hosoi, Masayuki
    DIABETES, 2010, 59 : A551 - A551